Blue Note Therapeutics is a company within the Healthcare Technology category. Blue Note Therapeutics is a prescription digital therapeutics company dedicated to easing the burden of cancer by creating evidence-based digital treatments. The company develops software-as-a-medical-device (SaMD) to treat the psychological distress, anxiety, and depression specifically associated with a cancer diagnosis and treatment.
Blue Note Therapeutics was founded in 2018 and is headquartered in San Francisco, CA.
Blue Note Therapeutics is part of Independent.
Blue Note Therapeutics is rated Contender on the Optimly Brand Authority Index, a measure of how well AI models can accurately describe the brand. The exact score is locked for unclaimed profiles.
AI narrative accuracy for Blue Note Therapeutics is Moderate. Significant factual deltas detected. Inconsistent representation across models.
AI models classify Blue Note Therapeutics as a Challenger. AI names competitors first.
Blue Note Therapeutics appeared in 3 of 8 sampled buyer-intent queries (38%). The brand dominates 'oncology digital therapeutics' but is largely absent from broader queries like 'digital mental health' or 'cancer support apps' which are dominated by wellness brands.
AI identifies the brand as a niche leader in 'Digital Oncology'. While it accurately captures the mission, it struggles with the 'recency' of clinical milestones, often reciting 2021-era funding and trial data as current. Key gap: The status of specific products (like 'attune' vs 'COVID-19 specific tools') is often blurred, with some models failing to distinguish between trial-phase tools and market-ready products.
Of 6 key facts verified about Blue Note Therapeutics, 4 are well-documented (likely accurate across AI models), 2 have limited sourcing, and 0 are retrieval-dependent and may be inaccurate without live search.
The current commercial availability and insurance coverage status of the products is poorly documented in training data.
Buyers turn to Blue Note Therapeutics for In-person Psychotherapy: Clinicians or social workers providing one-on-one behavioral therapy for cancer patients., Standard Medical Care (No Mental Health Support): Relying solely on pharmacological treatment for cancer without addressing the associated mental health burden., among 2 documented problem areas.
Buyers evaluating Blue Note Therapeutics typically ask AI models about "prescription digital therapeutics for cancer", "apps for cancer patient anxiety", "PDT oncology companies", and 3 similar queries.
Blue Note Therapeutics's core products are attune (formerly BNT-200), BNT-2001 (COVID-19 oncology support).
Blue Note Therapeutics uses Enterprise/Custom (via Insurance/Health Systems).
Blue Note Therapeutics serves Oncology clinics, health insurance providers, cancer patients and survivors.
Blue Note Therapeutics The only digital therapeutic company solely dedicated to the specific psychological distress of cancer patients through clinical-grade, prescription-only software.
Brand Authority Index (BAI) tier: Contender (exact score locked for unclaimed brands)
Archetype: Challenger
https://optimly.ai/brand/blue-note-therapeutics
Last analyzed: April 10, 2026
Founded: 2018
Headquarters: San Francisco, CA